Carlo Cattrini, MD, University of Genoa, Genoa, Italy, comments on the 5-year follow-up results of the Phase II/III STAMPEDE (NCT00268476) trial evaluating abiraterone acetate plus prednisolone for patients with metastatic prostates cancer starting long-term hormone therapy. The primary outcome measure was overall-survival (OS). A sustained and significant improvement in OS was observed. The trial demonstrated moving treatment into the earlier settings compared to later significantly prolongs survival. This interview took place at the Molecular Analysis for Precision oncology (MAP) Congress 2022 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.